Introduction
Classical Hodgkin lymphoma (cHL) is a B-cell derived malignant lymphoproliferative disease diagnosed in approximately 0.4 persons pr. 100.000/yr (1) . Whilst current treatment strategies manage to cure more than 80 % of these patients, a substantial proportion still experience relapsing or refractory disease eventually progressing to death. In order to identify those patients that need novel treatment strategies, several scoring systems have been proposed, including the "International Prognostic Score" (IPS) (2) . The IPS is still considered the "gold standard" for assessing prognosis and has performed consistently well in independent data sets. However, it was originally designed for patients with advanced disease and is therefore less suitable for patients with a low-risk profile (3) . Morover, recent early interim positron-emission tomography analysis has been shown to have a prognostic value superior to that of IPS in advanced stage cHL (4) .
The tumor lesion in cHL is characterized by a minority of neoplastic Hodgkin and ReedSternberg (HRS) cells, often representing as little as 1 % or less of the total cell population. The HRS cells are embedded in a heterogeneous background of nonneoplastic bystanders, mostly B-and T-cells, but also including macrophages, eosinophils, basophils and plasma cells. There has recently been increasing interest in these bystander cells, both in order to better understand the underlying biology of the disease and in order to identify new biological markers for prognostic and therapeutic purposes. Although, previous studies have suggested that bystander cells such a s eosinophils, mast cells (5;6) and T-cell subsets (7) might be of prognostic importance, no specific biological markers have yet been identified as reliable tools for pretherapeutic risk assessment.
A possible prognostic role for lymphoma associated macrophages (LAMs) has been suggested in several different lymphoproliferative entities, including recently cHL (8). For example, in follicular lymphoma, a number of studies have indicated that an increased content of CD68-positive LAMs is associated with an adverse prognostic impact, both with regard to event-free and to overall survival (OS) (9;10). In cHL, a considerable variation in the number of intra-tumoral macrophages has been observed (11). Recent gene expression profiling data showed a correlation between upregulation of genes related to intra-tumoral macrophages infiltration (STAT1, ALDH1A1) and poor treatment response suggesting an underlying tumor promoting role for these cells (12).
In the current study, we quantified the macrophage content in cases of cHL, a s measured by immunohistological expression of the two macrophage associated markers CD68 and CD163. We correlated the expression levels of these markers with pre-therapeutic clinico-pathological features and assessed their possible effect on outcome in cHL.
Design and Methods

Patients
We identified a total of 428 patients histopathologically diagnosed with Hodgkin lymphoma (HL) between 1990 and 2007 at Aarhus University Hospital, and in whom no other concurrent or previous malignancies were found. None of the patients was HIVpositive. All primary diagnostic tumor biopsies were reviewed and reclassified according to the WHO classification of tumors of the haemopoietic and lymphoid tissues (13). 
Tissue samples
A total of 288 formalin-fixed, paraffin-embedded tissue blocks from diagnostic cHL biopsies were retrieved from the archives of 10 participating Danish pathology departments.
Immunohistochemistry and In situ hybridization (ISH)
All immunohistochemical stains were performed on the Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ) using 4 _m paraffin tissue sections. The primary antibodies used in this study were: anti-CD68 (clone KP-1, dilution 1:800; Dako, Glostrup, Denmark), anti-CD163 (clone 10D6, dilution 1:50; Novocastra, Newcastle, UK) and anti-latent membrane protein-1 (LMP-1) (clones CS 1-4, dilution 1:100; Dako). All slides were incubated with the primary antibodies for 32 min at 37°C. For primary antibody detection the Ventana Ultraview™ DAB detection kit was used. For LMP-1 staining, the signal was enhanced with a Ventana amplification kit.
Slides were counterstained with hematoxylin. Non-isotopic ISH for Epstein-Barr virus (EBV)-encoded RNAs 1 and 2 (EBER) was performed and scored as described (16).
Tissue microarray construction
Six TMA blocks containing triplicate 1 mm cores from each patient sample were constructed with a manual tissue microarrayer (Beecher Instruments, Sun Prairie, WI), according to standard guidelines(17). Each block also contained samples of normal lymph node, placenta, kidney, and liver tissue as internal controls and for TMA landmarking.
Stereological analysis for the quantification of CD68 and CD163 expression
Quantification of immunhistochemical stains was performed by stereological analysis using a light microscope equipped with a computer assisted stereology system (CAST, Points hitting either necrosis or artefacts were ignored. In order to evaluate the intraobserver variation the Pearson correlation coefficients were calculated in 10% of the patients (n=30). The inter-observer variation was estimated in 10 patients that were chosen in a systematic, random manner. Variability between readings was also assessed by difference-average plots in concordance with the Bland-Altman method (19) . The intra-observer variation was found to be excellent for both CD68 and CD163 with Pearson correlation coefficients of 0.95 and 0.97, respectively. The two readings of CD68 had a mean deviation of -0.63% (95% CI: -1.4-0.13) and a 95% prediction interval (PI) from -4.7% to 3.5%. Considering CD163, the mean deviation was -0.18 (95% CI: -1.6-1.2) and with a 95% PI ranging from -7.7 to 7.4. Pearson correlation coefficients for inter-observer variation with CD68 and CD163 were 0.99 and 0.97, respectively. The inter-observer variation for CD68 had a mean deviation of 0.06% (95% CI: -0.6-0.7) and a 95% PI from -3.5% to 3.7%, while CD163 had a mean deviation of 2.2% (95% CI: -0.5-4.9) and a 95% PI from -5.7% to 9.7%.
Statistical analysis
Patient characteristics were compared using the Wilcoxon rank-sum test and the Kruskal-Wallis equality-of-populations rank test. The follow-up time was defined as the time from diagnosis to either last follow-up or a given event. Event-free survival (EFS) was measured from the date of diagnosis to either disease progression or discontinuation of treatment for any reason or censoring date. OS was measured from 
Results
Clinico-pathological features
The main clinical and histopathological features at presentation of the study cohort are summarized in Table I . The patient population had a median age of 37 years and a male/female ratio of 1. 
CD68 and CD163 expression
The staining patterns of both CD68 and CD163 ranged from cases with almost no expression to cases where the macrophage signal was predominant (figure 1). We found a higher AF for CD163 positivity compared with CD68, with median values of 7.5 % (range 0.1-63.4%) and 4.4 % (range, 0.3-30.7%), respectively.
The architectural pattern of macrophage infiltration varied from being diffuse and homogeneous to a more rosetting pattern. This rosetting was seen in both NS and mixed cellularity (MC) subtypes and seemed unrelated to the nodules that otherwise characterized NS architecture. As expected, both macrophage markers had a higher expression in the MC cases as compared to NS.
CD68 and CD163 expression and clinico-pathological features
Correlations between the results of macrophage stains CD68 and CD163 and clinicopathological features are listed in table I. Higher levels of CD68 and CD163 expression were correlated with the presence of EBV in the tumor cells (p=0.001 and 0.0002, respectively) and, consequently, also with the MC subtype. As expected, the majority of MC cases (68 %) were EBV positive as opposed to non-MC histology, where EBV was found in 26 % of the cases (p<0.001). However, even excluding the MC subtype from the analysis, the significant correlation between EBV and high CD163 persisted (p=0.03), whereas the corresponding correlation for CD68 was slightly weakened. (p=0.06).
Overexpression of both CD68 and CD163 also correlated to disseminated clinical stage and high CD163 expression alone to presence of B-symptoms and an IPS > 2.
Correlation between CD68 and CD163 expression and patient outcome
At univariate level, we found high CD68 and CD163 expression to correlate with an adverse outcome (table II) . The 10-year OS was 82% for cases with low and 61% for cases with high CD68 expression. Corresponding values for CD163 were 81% and 64%, respectively. Both a high CD68 and high CD163 expression correlated with poorer EFS. The 10-year EFS for high and low CD68 expression was 61% end 43%, respectively. The corresponding values for CD163 expression were 62% and 42%
( Figure 2 ).
At multivariate level, overexpression of CD68, but not CD163, had a significant predictive impact on OS ( However, it has been argued that the M1/M2 model is oversimplifying a much more complex macrophage biology and another nomenclature based on these cells involvement in host defense, wound healing and immune regulation has been proposed (24) . There is increasing experimental evidence that macrophages promote cancer initiation by facilitating an inflammatory environment that is mutagenic and growth enhancing and that they support tumor progression by stimulating angiogenesis, tumor cell migration, and suppressing antitumor immunity (25) . In contrast to the binary M1/M2 model, a definition of tumor-associated macrophages composed by several distinct populations with greater overall similarity to macrophages involved in developmental processes has now been suggested (25) .
In order to broadly cover the macrophage population present in cHL lesions, we used antibodies directed against CD68 and CD163, both of which are considered to be macrophage-associated antigens. CD68 is widely used as a pan-macrophage marker and has been shown to correlate with an adverse prognosis in a variety of malignancies, e.g. follicular lymphoma (26) . CD163 is a glycoprotein belonging to the cysteine-rich scavenger receptor superfamily (27) and has been suggested to be a more narrow macrophage marker than CD68 (28) . It is upregulated in macrophages stimulated by interleukin-10 and dexamethasone (29) . A high number of CD163-positive tumorinfiltrating macrophages has been shown to have an unfavorable prognostic impact in a variety of malignancies, e.g. pancreatic cancer (30) , malignant melanoma (31) and, more recently, also lymphoma (32) . In our material, we found higher expression of CD163 as compared to CD68. This finding is in keeping with previous studies (31;33) that have reported higher counts of tumor-infiltrating CD163 compared with CD68 macrophages in other malignancies such as malignant melanoma and leiomyosarcomas.
The results of our study support the prognostic importance of tumor-infiltrating macrophages in cHL. At the univariate level, high expression of both CD68 and CD163
in the tumor microenvironment was significantly associated with adverse prognosis.
However, after a multivariate analysis, CD68 retained a significant influence on OS, while CD163 did not. A possible explanation could be that CD68 covers a broader range of cells involved in the immune response and thereby better reflects the cellular microenvironment than the more lineage-specific CD163 staining. Furthermore, we observed that the adverse impact of a high CD68-count persisted also when cases of NS histology were analyzed separately. This finding suggests that the predictive value of CD68 is independent of histological subtype. Interestingly, both macrophage-associated markers were found to be strongly correlated with EBV-positivity. This held true even after removal of the EBV-associated MC subtype from the analysis. Consistent with this finding, a recent molecular profiling study in cHL, showed that the genes for CD68 and CD163 belonged to a large group of genes found to be upregulated in EBV+ cases (34) . In terms of methodology, our study quantified immunhistochemical stains using a computer assisted stereology system. Whether this method will find a place as a routine diagnostic tool remains to be seen. However, its labor-intensiveness will probably limit its use to the domain of clinical translational research, whereas semi-quantitative methods are more likely to be broadly applied.
Very recently, Steidl et al. published a study on cHL which also suggests that lymphomaassociated macrophages are of prognostic significance in this disease (8). Using microarrays, they identified a gene-expression signature of tumor-associated macrophages that correlated with shortened survival. Against the background of this gene-expression profile, they evaluated the number of intra-tumoral macrophages in an independent cohort of 166 cHL patients using CD68 immunostains. In that study CD68
was not independently associated with progression-free survival, but an association between the CD68-positive macrophage count and disease-specific survival at both univariate and multivariate level was found (8). Despite of some methodological differences in quantifying CD68-positive macrophages, the findings of Steidl et al. are in line with the results of our analysis. Hence, the present study provides an important set of data validating the role of CD68 immunohistochemistry as a biomarker in cHL, whose clinical usefulness should be tested prospectively.
In summary, quantification of CD68 and CD163 expression in the non-neoplastic cellular microenvironment of cHL lesions implicates the number of tumor infiltrating macrophages as a novel and important prognostic factor in this lymphoma. We found DOI: 10.3324/haematol.2010.031542 the prognostic impact of CD68 to be more marked than that of CD163. Both antigens were associated with tumor positivity for EBV. In cHL, as in other lymphoma subtypes,
there is now specific evidence that the microenvironment plays an important role in the biology and prognosis of the disease. This observation may contribute to an improved understanding of the pathogenesis of cHL and may provide new biomarkers for outcome prediction and novel therapeutic targeting.
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